{"id": "1342185216157372423", "creation": 1608836866.0, "user_id": "1233901069366771712", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 1, "like_count": 2, "quote_count": 0}}, "text": ".@Novavax vs .@InovioPharma -  Which COVID-19 Play Is More Compelling?\ud83e\udd14\n\nIn terms of #COVID19, $NVAX is further along in #vaccine development and has signed supply &amp; licensing deals with 7 countries. $INO has no supply deals to date.\n\n#investment #stocks https://t.co/hJpR1MOmIf", "first_save": 1634559108.199414, "hashtags": ["#COVID19", "#VACCINE", "#INVESTMENT", "#STOCKS"]}